Enanta Pharmaceuticals (NASDAQ:ENTA) is a clinical‐stage biotechnology company headquartered in Watertown, Massachusetts, focused on the discovery and development of small‐molecule antivirals. Since its founding in 1998 by a team of medicinal chemists, Enanta has leveraged a structure‐guided chemistry platform to identify novel viral targets and rapidly advance therapeutic candidates from early discovery to the clinic.
The company’s pipeline spans hepatitis C virus (HCV), respiratory syncytial virus (RSV), coronaviruses and other viral diseases. In collaboration with AbbVie, Enanta discovered the HCV protease inhibitors glecaprevir and pibrentasvir—key components of a pan‐genotypic regimen that has been approved for global use. Enanta is also advancing EDP-938, a first-in-class RSV nucleoprotein inhibitor undergoing late‐stage clinical trials, alongside investigational therapies targeting SARS-CoV-2 and hepatitis B.
Enanta partners with leading pharmaceutical companies, including AbbVie and Roche, to accelerate development timelines and expand geographic reach across North America, Europe and Asia-Pacific. The company’s integrated R&D facility in the Boston area brings together experts in medicinal chemistry, virology, pharmacology and translational science to support its discovery and clinical programs.
Led by President and Chief Executive Officer Jay Luly, Enanta is guided by a board of directors composed of seasoned professionals in biotechnology, pharmaceutical development and finance. Under this leadership, the company continues to invest in innovative antiviral modalities aimed at addressing unmet medical needs and improving patient outcomes worldwide.
